Predictors of overall survival in patients with metastatic castration-resistant prostate cancer

Objective: to estimate overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer ( mCRPC), who have received currently available drugs and to identify the predictors of OS. Subjects and methods. The case histories of 112 patients with mCRPC treated at the N.N. Blokhin Russian Cancer Research Center in 2005 to 2014 were retrospectively analyzed. All the patients had received standard regimens based on docetaxel, cabazitaxel, abiraterone acetate in combination with prednisolone. Results. Whatever the treatment option was, three-year OS rate was 32.0 +/- 5.44 %; median survival was 24.3 months. The following poor prognostic factors for OS were pain syndrome; an ECOG performance status score of 2; the levels of prostate-specific antigen >= 288 ng/ml, lactate dehydrogenase >= 450 U/l, alkaline phosphatase >= 250 U/l, calcium < 2.28 mmol/l, and hemoglobin < 11.5 g/dl; as well as < 24 months' duration of a response to hormonal therapy. Conclusion. The use of standard drug treatment regimen for mCRPC may increase survival in this category of patients to achieve 3-years OV; and the identified factors of OV may aid in choosing treatment policy.